Science 1st - Oncology: Harnessing Cancer Immunotherapies of the Future
Science 1st - Oncology: Harnessing Cancer Immunotherapies of the Future
LabCentral , 700 Main Street , Cambridge , MA 02139
September 30, 2015 from 16:00 PM to 18:30 PM (EDT)
$10 - $35
Immunotherapy harnesses the body's own immune system to fight cancer and it is revolutionizing cancer treatment. Unprecedented outcomes have been observed in cancers that were once perceived as hopeless such as melanoma and lung cancer. Nonetheless, not all patients respond to treatment, and an understanding of efficacy drivers is lacking. Can co-clinical trials provide the necessary mechanistic insight to identify the right immunotherapies and combinations to improve patient outcomes and speed up drug approvals?
Johnson & Johnson Innovation, JLABS (JLABS) is bringing together top experts to discuss the latest developments, challenges, and opportunities with the co-clinical approach to immunotherapy development. Join Dr. Jianzhu Chen, Dr. Wendy Garrett, and Dr. Kwok-Kin Wong as they present the latest research in this area and engage in a panel discussion to obtain insights into novel immunotherapies of the future.
2:00pm | Registration Opens
2:30pm | Presentations
3:15pm | Panel discussion
4:00pm | Reception
4:30pm | Close
Jianzhu Chen | Professor, Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology read bio»
Wendy Garrett | Associate Professor, Immunology & Infectious Diseases, Harvard T. H. Chan School of Public Health read bio»
Kwok-Kin Wong | Professor of Medicine, Dana-Farber Cancer Institute/Harvard Medical School read bio»
[moderator] Kathryn Packman | Sr. Scientific Director Tumor Biology, Janssen Research & Development, LLC read bio»
$25 | General Public
$15 | Student/Academic
$35 | At the door
700 Main St
Cambridge, MA 02139
About the Science First series:
The purpose of the Science First series, sponsored by Johnson & Johnson Innovation, JLABS, is to bring together top experts to explore a pressing topic in their scientific field. It is a chance for local scientists, researchers, and entrepreneurs to present and dialogue on new discoveries, advancing techniques, and other cutting-edge science themes.
Jianzhu Chen, Ph.D. | Professor, Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology
Jianzhu Chen is the Ivan R. Cottrell Professor of Immunology and Professor of Biology at Koch Institute for Integrative Cancer Research and Department of Biology at MIT. He is also the lead Principle Investigator of the Infectious Disease Interdisciplinary Research Group of Singapore-MIT Alliance for Research and Technology (SMART). Dr. Chen's research seeks fundamental understanding of the immune system as well as its application in disease intervention. Recently, his research activity has focused on developing humanized mouse technology for modeling human diseases with autologous immune system and therapeutic development. Dr. Chen received a B.S. degree from Wuhan University in China and a Ph.D. degree from Stanford University. He was a postdoctoral fellow and then an instructor at Harvard Medical School before he joined the faculty in the Department of Biology at MIT. Dr. Chen is also a visiting professor at Institute for Molecular and Cell Biology in Singapore, Institute of Biophysics, Chinese Academy of Sciences in Beijing, and the First Affiliate Hospital of Jilin University in Changchun, China.
Connect with Jianzhu:
Wendy Garrett, M.D., Ph.D. | Associate Professor, Immunology & Infectious Diseases, Harvard T. H. Chan School of Public Health
Dr. Garrett is an Associate Professor at the Harvard TH Chan School of Public Health. Dr. Garrett is a physician at Dana-Farber Cancer Institute and Brigham and Women's Hospital. She is a member of the gastrointestinal cancer center at Dana-Farber Cancer Institute and is board certified in medical oncology and internal medicine. Her laboratory is focused on defining the dynamic interactions between the mucosal immune system and gut microbiota. The Garrett laboratory's experimental questions are grounded in understanding how interactions between intestinal microbial communities and the immune system contribute to the development of inflammatory bowel disease and colorectal cancer. Dr. Garrett has received the following awards for her research: a Damon Runyon Foundation Fellowship, a Burroughs Wellcome Career in Medical Sciences Award, a V Foundation Scholar, a Cancer Research Institute Investigator Award, and a Searle Scholars Award. Dr. Garrett was educated at Yale University and pursued post-graduate clinical education and research fellowships at Harvard.
Connect with Wendy:
Kwok-Kin Wong, M.D., Ph.D. | Professor of Medicine, Dana-Farber Cancer Institute/Harvard Medical School
Kwok-Kin Wong, M.D., Ph.D., is a Professor of Medicine at the Dana-Farber Cancer Institute/Harvard Medical School and Scientific Director of The Belfer Institute for Applied Cancer Science. Dr. Wong's research activities focus on understanding the pathogenesis and genetic alterations involved in lung tumorigenesis, as well as testing novel lung cancer therapeutics in vivo. Toward this goal, Dr. Wong's laboratory has generated multiple genetically engineered inducible mouse models of lung cancers based on recently discovered lung cancer relevant oncogenic mutations. These models have proved invaluable for understanding the molecular mechanisms of lung cancer initiation and progression, as well as for novel targeted therapeutic testings. Dr. Wong was elected to the American Society of Clinical Investigation in 2007 and Association of American Physicians in 2015. He is a recipient of the Sidney Kimmel Foundation Scholar Award and the Tisch Foundation Solid Tumor Scholar Award. He was also the recipient of the Team Science Award from the American Association for Cancer Research in 2010. After earning his MD and PhD from the College of Physicians and Surgeons at Columbia University, Dr. Wong completed his internship and residency in Medicine at Massachusetts General Hospital. He subsequently completed fellowship training in the Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in Medical Oncology in 2001.
[moderator] Kathryn Packman, Ph.D. | Scientific Director Oncology Collaborations, Janssen Research & Development, LLC
Dr. Packman is Scientific Director of Oncology Collaborations at Janssen Research & Development, LLC. From the Johnson & Johnson Innovation Center in Boston, she leads academic and biotechnology research collaborations for the Oncology therapeutic area located on the East Coast of the U.S. In this role, she brings cuttingedge technologies and deep biological insight to accelerate development of transformative medicines for cancer patients.
Dr. Packman is an in vivo pharmacology leader with extensive preclinical drug discovery experience. Dr. Packman was head of preclinical oncology research at the Roche Translational and Clinical Research Center, where she defined the small molecule externalization strategy and delivered preclinical research support through academic and biotechnology alliances. Prior to that, she led preclinical tumor biology at Roche Pharmaceuticals for 10 years, where her laboratory examined drug efficacy and biological mechanisms of action in vivo. This work culminated in the advancement of ten drugs with companion biomarkers into clinical investigation, including CDK inhibitor R547, multikinase inhibitor R1530, MEK 1/2 inhibitor RO5068760, Gamma Secretase inhibitor RG4733, antiPlGF MAb RG7334, antiTweak MAb RG7212, firstinclass p53MDM2 antagonists RG7112 and RG7388 currently under clinical investigation, and the marketed BRAFV600 inhibitor vemurafenib (Zelboraf) for the treatment of melanoma. Dr. Packman's laboratory also focused on modulation of dose, schedule, and combination therapy to optimize tumor apoptotic response while limiting drug toxicity. Their work provided the basis for clinical investigation of the dosedense regimen for the marketed drug capecitabine (Xeloda) in breast and colorectal cancer, as well as intermittent schedules for p53MDM2 antagonist RG7388 under clinical investigation in acute myeloid leukemia (AML) and prostate cancer. Dr. Packman has published over 40 peerreviewed research articles and 6 patents. She also served as an Adjunct Professor in the Graduate School of Biomedical Sciences at the Rutgers New Jersey Medical and Dental School for 10 years. Dr. Packman earned her BSc. Degree in Biology at the State University of New York at Geneseo, and a Ph.D. in Cellular and Molecular Biology at the University of Notre Dame.
Connect with Kathryn: